US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Artiva Biotherapeutics, Inc.

2.10

+0.14007.14%

Post-market: 2.100.00000.00%18:45 EDT

Volume:212.21K

Turnover:443.85K

Market Cap:51.16M

PE:-0.50

High:2.14

Open:1.98

Low:1.96

Close:1.96

Loading ...

Overview Company News Filings

Artiva Biotherapeutics Is Maintained at Buy by Needham

Needham Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics: 64% Complete Response Rate With Allonk + Rituximab in Heavily Pretreated Patients That Were NaÏVe to Prior CAR-T Cell Therapy

THOMSON REUTERS

Artiva Biotherapeutics Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability for Allonk® in Combination With Rituximab in Patients With B-Cell-Non-Hodgkin Lymphoma at the Asgct 28TH Annual Meeting

THOMSON REUTERS

Artiva Biotherapeutics Inc: Median Duration of Response for Allonk + Rituximab Not yet Reached and Is at Least 19.4 Months

THOMSON REUTERS

Artiva Biotherapeutics Inc: Allonk + RTX Was Well-Tolerated Among 45 Patients Dosed

THOMSON REUTERS

Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating

Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance

Artiva Biotherapeutics sees cash runway into 2Q27

Artiva Biotherapeutics Q1 EPS $(0.83) Misses $(0.72) Estimate

Artiva Biotherapeutics Inc: Qtrly Loss per Share $0.83

THOMSON REUTERS

Artiva Biotherapeutics Inc: Cash Runway Extension Into Q2 2027

THOMSON REUTERS

Artiva Biotherapeutics Inc Q1 Shr View $-0.71 -- Lseg Ibes Data

THOMSON REUTERS

Press Release: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Names New Chief Medical Officer

Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham

Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ARTV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARTV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":2.1,"timestamp":1749240000000,"preClose":1.96,"halted":0,"volume":212213,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"18:45 EDT","volume":1858,"amount":3900.834,"timestamp":1749249957898},"delay":0,"floatShares":5916834,"shares":24363119,"eps":-4.183957,"marketStatus":"Market Closed","change":0.14,"latestTime":"06-06 16:00:00 EDT","open":1.98,"high":2.14,"low":1.96,"amount":443854.312363,"amplitude":0.091837,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.183957,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":1.96,"preHourTrading":{"tag":"盘前","latestPrice":1.8538,"preClose":1.96,"latestTime":"08:19 EDT","volume":149,"amount":286.4006033,"timestamp":1749212364372},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"18:45 EDT","volume":1858,"amount":3900.834,"timestamp":1749249957898},"volumeRatio":2.1352575647894803},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","floatShares":5916834,"roa":"-33.30%","roe":"-68.14%","lyrEps":-5.806365,"volumeRatio":2.1352575647894803,"shares":24363119,"dividePrice":0,"high":2.14,"amplitude":0.091837,"preClose":1.96,"low":1.96,"week52Low":1.78,"pbRate":"0.30","week52High":17.31,"institutionHeld":0,"latestPrice":2.1,"eps":-4.183957,"divideRate":0,"volume":212213,"delay":0,"ttmEps":-4.183957,"open":1.98,"prevYearClose":10.08,"prevWeekClose":1.93,"prevMonthClose":1.93,"prevQuarterClose":3,"fiveDayClose":1.93,"twentyDayClose":2.18,"sixtyDayClose":6.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARTV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535814810","title":"Artiva Biotherapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2535814810","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535814810?lang=en_us&edition=fundamental","pubTime":"2025-05-15 18:17","pubTimestamp":1747304220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 06:17 ET (10:17 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2535007253","title":"Needham Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007253?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253713,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) today and set a price target of $18.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-remains-a-buy-on-artiva-biotherapeutics-inc-artv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-remains-a-buy-on-artiva-biotherapeutics-inc-artv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2535708120","title":"Artiva Biotherapeutics: 64% Complete Response Rate With Allonk + Rituximab in Heavily Pretreated Patients That Were NaÏVe to Prior CAR-T Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2535708120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535708120?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8JYN2C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2535108109","title":"Artiva Biotherapeutics Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability for Allonk® in Combination With Rituximab in Patients With B-Cell-Non-Hodgkin Lymphoma at the Asgct 28TH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2535108109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535108109?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8JYN2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2535081707","title":"Artiva Biotherapeutics Inc: Median Duration of Response for Allonk + Rituximab Not yet Reached and Is at Least 19.4 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2535081707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535081707?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8JYN2C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2535081093","title":"Artiva Biotherapeutics Inc: Allonk + RTX Was Well-Tolerated Among 45 Patients Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2535081093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535081093?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8JYN2C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2534168455","title":"Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2534168455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534168455?lang=en_us&edition=fundamental","pubTime":"2025-05-09 02:45","pubTimestamp":1746729942,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) today and set a price target of $23.00. G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/artiva-biotherapeutics-strategic-delay-and-expanded-research-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/artiva-biotherapeutics-strategic-delay-and-expanded-research-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"gpt_icon":0},{"id":"2533130729","title":"Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2533130729","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533130729?lang=en_us&edition=fundamental","pubTime":"2025-05-08 23:15","pubTimestamp":1746717355,"startTime":"0","endTime":"0","summary":"Tyler Van Buren, an analyst from TD Cowen, has initiated a new Buy rating on Artiva Biotherapeutics, Inc. (ARTV). Tyler Van Buren has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/artiva-biotherapeutics-inc-strategic-advancements-and-market-potential-in-biotherapeutics-highlighted-by-phase-iia-trial-initiation-and-fda-clearance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/artiva-biotherapeutics-inc-strategic-advancements-and-market-potential-in-biotherapeutics-highlighted-by-phase-iia-trial-initiation-and-fda-clearance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2533187232","title":"Artiva Biotherapeutics sees cash runway into 2Q27","url":"https://stock-news.laohu8.com/highlight/detail?id=2533187232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533187232?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:40","pubTimestamp":1746708047,"startTime":"0","endTime":"0","summary":"As of March 31, 2025, Artiva had cash, cash equivalents, and investments of $166.0 million which is expected to fund operations into Q2 2027. Publi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/artiva-biotherapeutics-sees-cash-runway-into-2q27?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/artiva-biotherapeutics-sees-cash-runway-into-2q27?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2533184917","title":"Artiva Biotherapeutics Q1 EPS $(0.83) Misses $(0.72) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533184917","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533184917?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:11","pubTimestamp":1746706300,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.72) by 15.28 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45283333/artiva-biotherapeutics-q1-eps-0-83-misses-0-72-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2533518438","title":"Artiva Biotherapeutics Inc: Qtrly Loss per Share $0.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2533518438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533518438?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:05","pubTimestamp":1746705953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG36Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2533184841","title":"Artiva Biotherapeutics Inc: Cash Runway Extension Into Q2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2533184841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533184841?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:05","pubTimestamp":1746705953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG36Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2533184388","title":"Artiva Biotherapeutics Inc  Q1 Shr View $-0.71 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2533184388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533184388?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:05","pubTimestamp":1746705953,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG36Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2533184327","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2533184327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533184327?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:00","pubTimestamp":1746705600,"startTime":"0","endTime":"0","summary":"IND clearance and initiation of global basket trial exploring AlloNK + rituximab in refractory rheumatoid arthritis, Sjgren's disease, idiopathic inflammatory myopathies and systemic sclerosis. First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjgren's disease in the U.S.Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026. Dr. Aslan continued, \"Our longer-term aggressive B-NHL data is maturing into a leading data set, in line with approved auto-CAR-T therapies, providing proof of concept of AlloNK's ability to deplete B-cells deeply and durably. We remain well capitalized to gene","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","ARTV","BK4022","R","RA","BK4232"],"gpt_icon":0},{"id":"2531298353","title":"Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298353","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298353?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:35","pubTimestamp":1745872500,"startTime":"0","endTime":"0","summary":"Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK + rituximab for the treatment of B-cell driven diseases in a community setting. Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process. In addition, the Company will have a poster presentation featuring the scalability and consistency of the AlloNK manufacturing process.Abstract 858 – AlloNK Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Abstract 1765 – AlloNK: A Scalable and Consistent NK Cell Therapy in Development for Treatment of Oncology and Autoimmune Diseases. Abstracts are currently available on the ASGCT website. Following the presentations, copies will be available on the \"Scientific Posters & Publications\" section of the “Events & Presentation” page on the Company's website.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/artiva-biotherapeutics-present-longer-term-203500617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2526823264","title":"Artiva Biotherapeutics Names New Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526823264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526823264?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:57","pubTimestamp":1744145820,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics named Subhashis Banerjee as its chief medical officer, succeeding Thorsten Graef, who will continue to serve the company as a strategic adviser.Banerjee is a trained rheumatologist and immunologist with more than two decades of clinical development experience in autoimmune diseases, the San Diego-based company said Tuesday.His appointment will help the company progress the clinical development of its treatment of B-cell driven autoimmune diseases, Chief Executive Fred Aslan said.Prior to joining Artiva, Banerjee helmed Bristol Myers Squibb's rheumatology and dermatology global development arm. Previously, he held an executive position at Vyne Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2526823067","title":"Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2526823067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526823067?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:45","pubTimestamp":1744145135,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (ARTV) announced the appointment of Subhashis Banerjee as chief medical officer. Banerjee was most recently disease area hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/artiva-cmo-thorsten-graef-switches-to-advisor-role-subhashis-banerjee-succeeds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/artiva-cmo-thorsten-graef-switches-to-advisor-role-subhashis-banerjee-succeeds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IIM","BK4139","BK4232","BMS","R","RA","SLE","BK4077","BK4022","ARTV"],"gpt_icon":0},{"id":"2525928318","title":"Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2525928318","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525928318?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:53","pubTimestamp":1744116780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:53 ET (12:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2525601798","title":"Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2525601798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525601798?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:57","pubTimestamp":1744109876,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) and keeping the price target at $23....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-artiva-biotherapeutics-amid-strategic-manufacturing-and-regulatory-support?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-artiva-biotherapeutics-amid-strategic-manufacturing-and-regulatory-support?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARTV"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARTV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"ARTV","fiscalQuarterEnding":"2025/03","expectedEps":-0.68,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.83}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARTV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARTV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARTV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARTV","date":"2025-06-06","current":-0.665798,"percent":0.971429,"low":-11.820615,"twenty":-9.028935,"median":-3.995633,"eighty":-0.946604,"high":-0.614844,"avg":-4.691914,"sd":3.683313,"marketCap":47751713},"quantilePoints":[{"date":"2024-08-02","current":-10.391793,"twenty":-10.391793,"median":-10.391793,"eighty":-10.391793,"marketCap":269833291},{"date":"2024-08-09","current":-9.862789,"twenty":-10.391793,"median":-10.042112,"eighty":-9.943484,"marketCap":256097171},{"date":"2024-08-16","current":-10.185571,"twenty":-10.248334,"median":-10.131774,"eighty":-9.95245,"marketCap":264478532},{"date":"2024-08-23","current":-8.939273,"twenty":-10.248334,"median":-10.051078,"eighty":-9.342751,"marketCap":232117163},{"date":"2024-08-30","current":-8.088598,"twenty":-10.185571,"median":-9.943484,"eighty":-9.046867,"marketCap":263081639},{"date":"2024-09-06","current":-8.893463,"twenty":-10.142533,"median":-9.800025,"eighty":-8.930111,"marketCap":289259885},{"date":"2024-09-13","current":-8.019798,"twenty":-10.131774,"median":-9.459311,"eighty":-8.763533,"marketCap":260843926},{"date":"2024-09-20","current":-8.759053,"twenty":-10.07439,"median":-9.028935,"eighty":-8.450238,"marketCap":284888199},{"date":"2024-09-27","current":-9.946342,"twenty":-10.07439,"median":-9.323455,"eighty":-8.581333,"marketCap":323504758},{"date":"2024-10-04","current":-11.499524,"twenty":-10.277026,"median":-9.57298,"eighty":-8.727691,"marketCap":374022017},{"date":"2024-10-11","current":-10.566121,"twenty":-10.505561,"median":-9.728296,"eighty":-8.794895,"marketCap":343663087},{"date":"2024-10-18","current":-9.543111,"twenty":-10.587029,"median":-9.800025,"eighty":-8.869568,"marketCap":310389700},{"date":"2024-10-25","current":-7.586699,"twenty":-10.505561,"median":-9.574426,"eighty":-8.581333,"marketCap":246757383},{"date":"2024-10-31","current":-7.579232,"twenty":-10.485041,"median":-9.464706,"eighty":-8.226879,"marketCap":246514511},{"date":"2024-11-08","current":-10.424244,"twenty":-10.485041,"median":-9.3863,"eighty":-8.226879,"marketCap":339048530},{"date":"2024-11-15","current":-4.166082,"twenty":-10.46953,"median":-9.378833,"eighty":-8.149728,"marketCap":255280837},{"date":"2024-11-22","current":-4.310765,"twenty":-10.439178,"median":-9.30416,"eighty":-7.969021,"marketCap":264146442},{"date":"2024-11-29","current":-5.065892,"twenty":-10.411264,"median":-9.046867,"eighty":-7.81669,"marketCap":310417611},{"date":"2024-12-06","current":-4.598149,"twenty":-10.334409,"median":-8.970887,"eighty":-7.365669,"marketCap":281756204},{"date":"2024-12-13","current":-4.233469,"twenty":-10.223229,"median":-8.939273,"eighty":-5.058757,"marketCap":259410023},{"date":"2024-12-20","current":-3.963922,"twenty":-10.173512,"median":-8.885996,"eighty":-4.852633,"marketCap":242893280},{"date":"2024-12-27","current":-4.17401,"twenty":-10.150694,"median":-8.781454,"eighty":-4.667914,"marketCap":255766623},{"date":"2025-01-03","current":-3.95203,"twenty":-10.131774,"median":-8.549971,"eighty":-4.598149,"marketCap":242164600},{"date":"2025-01-10","current":-4.066984,"twenty":-10.131774,"median":-8.396892,"eighty":-4.398368,"marketCap":249208505},{"date":"2025-01-17","current":-2.687539,"twenty":-10.07439,"median":-8.17661,"eighty":-4.337719,"marketCap":164681643},{"date":"2025-01-24","current":-2.477451,"twenty":-10.049285,"median":-8.109405,"eighty":-4.224748,"marketCap":151808300},{"date":"2025-01-31","current":-2.140518,"twenty":-10.011532,"median":-8.012331,"eighty":-4.193829,"marketCap":131162371},{"date":"2025-02-07","current":-1.823404,"twenty":-9.967928,"median":-7.881014,"eighty":-4.108209,"marketCap":111730908},{"date":"2025-02-14","current":-1.589533,"twenty":-9.948785,"median":-7.698708,"eighty":-3.978192,"marketCap":97400205},{"date":"2025-02-21","current":-1.502326,"twenty":-9.945199,"median":-7.508293,"eighty":-3.804572,"marketCap":92056553},{"date":"2025-02-28","current":-1.478543,"twenty":-9.911206,"median":-5.18038,"eighty":-2.77871,"marketCap":90599193},{"date":"2025-03-07","current":-2.0216,"twenty":-9.837683,"median":-5.059946,"eighty":-2.521847,"marketCap":123875572},{"date":"2025-03-14","current":-2.219796,"twenty":-9.795827,"median":-4.998506,"eighty":-2.343471,"marketCap":136020236},{"date":"2025-03-21","current":-1.601424,"twenty":-9.736345,"median":-4.76067,"eighty":-2.165887,"marketCap":98128885},{"date":"2025-03-28","current":-1.319282,"twenty":-9.624289,"median":-4.665536,"eighty":-2.054897,"marketCap":86245441},{"date":"2025-04-04","current":-0.946604,"twenty":-9.574715,"median":-4.606077,"eighty":-1.965312,"marketCap":61882322},{"date":"2025-04-11","current":-0.685729,"twenty":-9.561032,"median":-4.439593,"eighty":-1.797242,"marketCap":44828138},{"date":"2025-04-17","current":-0.857161,"twenty":-9.511749,"median":-4.37617,"eighty":-1.744126,"marketCap":56035173},{"date":"2025-04-25","current":-0.913063,"twenty":-9.383313,"median":-4.344458,"eighty":-1.606181,"marketCap":59689641},{"date":"2025-05-02","current":-0.883248,"twenty":-9.365642,"median":-4.233469,"eighty":-1.560992,"marketCap":57740592},{"date":"2025-05-09","current":-0.740531,"twenty":-9.335033,"median":-4.213649,"eighty":-1.495984,"marketCap":53111599},{"date":"2025-05-16","current":-0.723546,"twenty":-9.26085,"median":-4.193829,"eighty":-1.480232,"marketCap":51893443},{"date":"2025-05-23","current":-0.672592,"twenty":-9.079462,"median":-4.170046,"eighty":-1.376675,"marketCap":48238975},{"date":"2025-05-30","current":-0.696371,"twenty":-9.046867,"median":-4.104641,"eighty":-1.177664,"marketCap":49944393},{"date":"2025-06-06","current":-0.665798,"twenty":-9.028935,"median":-3.995633,"eighty":-0.946604,"marketCap":47751713}],"updateTime":1749393536418}}}